

# Integrated Filing (Finance) Ind AS

## BAJAJ HEALTHCARE LIMITED

### General Information

Scrip code*	539872
NSE Symbol*	BAJAJHCARE
MSEI Symbol*	NOTLISTED
ISIN*	INE411U01027
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	17-10-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	13-10-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date of board meeting	17-10-2025
Start time of board meeting	16:25:00
End date of board meeting	17-10-2025
End time of board meeting	16:47:00
Whether cash flow statement is applicable on company	true
Type of cash flow statement	Cash Flow Indirect

Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	
Whether the company has any related party?	true	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	true	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	false	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	true	
Latest Date on which RPT policy is updated	11-02-2025	
Indicate Company website link for updated RPT policy of the Company	<a href="https://www.bajajhealth.com/policies/">https://www.bajajhealth.com/policies/</a>	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	false	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	false	<a href="#">Textual Information(1)</a>

## Text Block

[Textual  
Information\(1\)](#)

During the quarter ended 30.09.2025, there is no default.

## Financial Results - Ind-AS

Amount in (Lakhs)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-07-2025	01-04-2025
	Date of end of reporting period	30-09-2025	30-09-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
Part I	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
1	<b>Income</b>		
	Revenue from operations	14,791.49	29,675.12
	Other income	165.29	253.06
	<b>Total income</b>	14,956.78	29,928.18
2	<b>Expenses</b>		
(a)	Cost of materials consumed	7,480.50	14,468.99
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(120.39)	949.92
(d)	Employee benefit expense	1,650.87	3,086.49
(e)	Finance costs	555.87	1,078.44
(f)	Depreciation, depletion and amortisation expense	708.21	1,271.86
(g)	<b>Other Expenses</b>		
1	Brokerage & Commission	100.98	202.91
2	Consumption of Stores Spares and Maintainence	606.03	1,245.65
3	Freight Forwarding & Transport	341.16	606.71
4	Insurance Expenses	125.32	180.53
5	Legal & Professional Expenses	173.54	389.63
6	Power and Fuel	565.79	1,133.29
7	Processing & Labour Charges	476.70	882.35
8	Travelling & Conveyence Expenses	53.08	169.42
9	Material Testing & Inspection Charges	74.96	144.21

10	Others	567.95	1,069.06
	<b>Total other expenses</b>	3,085.51	6,023.76
	<b>Total expenses</b>	13,360.57	26,879.46
3	<b>Total profit before exceptional items and tax</b>	1,596.21	3,048.72
4	Exceptional items	0.00	0.00
5	<b>Total profit before tax</b>	1,596.21	3,048.72
6	<b>Tax expense</b>		
7	Current tax	0.00	0.00
8	Deferred tax	351.35	586.49
9	<b>Total tax expenses</b>	351.35	586.49
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	<b>Net Profit Loss for the period from continuing operations</b>	1,244.86	2,462.23
12	Profit (loss) from discontinued operations before tax	(179.00)	(224.43)
13	Tax expense of discontinued operations	(45.06)	(56.49)
14	<b>Net profit (loss) from discontinued operation after tax</b>	(133.94)	(167.94)
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	<b>Total profit (loss) for period</b>	1,110.92	2,294.29
17	Other comprehensive income net of taxes	18.70	37.41
18	<b>Total Comprehensive Income for the period</b>	1,129.62	2,331.70
19	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	<b>Details of equity share capital</b>		
	Paid-up equity share capital	1,579.16	1,579.16
	Face value of equity share capital	5.00	5.00
22	Reserves excluding revaluation reserve		
23	<b>Earnings per share</b>		

i	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	3.95	7.80
	Diluted earnings (loss) per share from continuing operations	3.88	7.63
ii	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	(0.42)	(0.53)
	Diluted earnings (loss) per share from discontinued operations	(0.41)	(0.52)
iii	<b>Earnings per equity share (for continuing and discontinued operations)</b>		
	Basic earnings (loss) per share from continuing and discontinued operations	3.53	7.27
	Diluted earnings (loss) per share from continuing and discontinued operations	3.47	7.11
24	Debt equity ratio	0.45	0.45
25	Debt service coverage ratio	0.51	0.47
26	Interest service coverage ratio	3.87	3.83
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	<a href="#">Textual Information(1)</a>	

## Text Block

### [Textual Information\(1\)](#)

1 The above Financial Results of Bajaj Healthcare Limited the Company have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 17 October 2025. These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion. ' ' 2 The above unaudited financial results for the quarter and half year ended 30 Sept 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act 2013 Act read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing ' obligations and disclosure requirements Regulations 2015 as amended. ' ' 3 The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore the Company has identified only one reportable segment i.e. Pharmaceuticals. ' ' 4 In the year ended 31 March 2024 the Board of Directors had approved to sale/disposal of undertaking units on going concern basis situated at plot no. N92 L9.3 T30 MIDC Tarapur Taluka Boisar District Palghar Maharashtra and vacant industrial land situated at plot no. D2 CH 42 and D2 CH 43 Dahej industrial area GIDC Bharuch Gujarat which were acquired under SARFAESI ACT 2022 from Saraswat Bank and plot no.E62 and E63 MIDC Tarapur Taluka Boisar District Palghar Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations. The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale the assets have been recorded at their fair value on the date these assets has been classified as held for sale. Out of these one unit situated at plot no. N-92 was sold during the Quarter ended 31 March 2024. The total value of assets classified as held for sale represents lower of carrying value or fair value. ' ' The financial information from discontinued operations ' Particulars Quarter Ended Period ended

Year ended	' 30 Sept 2025	30 June 2025	30 Sept 2024	30 Sept 2024	31 March 2025	' Unaudited	Unaudited	Unaudited
Unaudited	Unaudited	Audited	' Total Income A	0.05	2.10	24.34	2.15	
30.48	58.07	' Total Expenses B	179.05	47.53	107.72	226.58	225.83	
459.18	' Loss before Tax from Discontinued Operations C = A - B							
-179.00	-45.43	-83.38	-224.43	-195.35	-401.11	' Tax Credit from Discontinued Operations D	-45.06	-11.43
-195.44	-56.49	-217.97	-57.78	' Loss after Tax from Discontinued Operations E = C - D				
-133.94	-34.00	112.06	-167.94	22.62	-343.33	' ' 5 The Board of Directors of the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra-Ordinary General Meeting EGM held on Wednesday 07 August 2024 through Video Conferencing VC Other Audio Visual Means OAVM approved the issue of 4044852 Equity Shares at Rs 338 per share including premium at Rs. 333 per share to Persons belonging to non-promoter category on preferential basis and the issue of convertible equity warrants 2079409 at Rs. 338 per warrant including premium at Rs. 333 per share to Persons belonging to promoter category as well as non-promoter category on preferential basis. The object of the issue is to repayment of term loan investment in capital expenditure and general corporate purposes. The Company has also obtained the in-principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024 post approval from Board the Company has allotted 3984852 no. of equity shares and 2079409 convertible warrants and has also filed the relevant form with Registrar of Companies Mumbai. The uncalled amount of share warrants as at 30 September 2025 is Rs. 5271.30 lakhs and will be received within 18 months from the allotment date of 19 September 2024. ' ' 6 The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. ' Particulars Rs in Lakhs ' Repayment & prepayment of secured/ unsecured loans from bank/NBFC 15000.00 ' General corporate purposes 225.90 ' Total 15225.90 ' ' 7 In April 2025 the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation Genrx on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act 1956. The acquisition was made for a total consideration of Rs. 1085 lakhs. ' Subsequently on 3 June 2025 the Company filed an application with the Hon'ble National Company Law Tribunal NCLT Mumbai seeking certain reliefs and concessions necessary for the effective		

	<p>implementation of the acquisition and takeover of Genrx as a going concern which is pending with NCLT as on 30 September 2025. Hence Genrx has not been considered a subsidiary for consolidation purpose pending requisite approvals from the NCLT as control defined under Ind AS 110 Consolidated Financial Statements is not established. '</p>
--	--

## Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-07-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
<b>1</b>	<b>Segment Revenue (Income)</b>		
	(net sale/income from each segment should be disclosed)		
	<b>Total Segment Revenue</b>		
	<b>Less: Inter segment revenue</b>		
	<b>Revenue from operations</b>		
<b>2</b>	<b>Segment Result</b>		
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>		
	<b>Total Profit before tax</b>		
	<b>i. Finance cost</b>		
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>		
	<b>Profit before tax</b>		
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>		
	<b>Segment Asset</b>		
	<b>Total Segment Assets</b>		
	<b>Un-allocable Assets</b>		
	<b>Net Segment Assets</b>		
<b>4</b>	<b>Segment Liabilities</b>		
	<b>Segment Liabilities</b>		
	<b>Total Segment Liabilities</b>		
	<b>Un-allocable Liabilities</b>		
	<b>Net Segment Liabilities</b>		

Disclosure of notes on segments

[Textual  
Information\(1\)](#)

## Text Block

[Textual  
Information\(1\)](#)

The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.

## Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-07-2025	01-04-2025
Date of end of reporting period	30-09-2025	30-09-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
<b>Other comprehensive income [Abstract]</b>		
<b>1 Amount of items that will not be reclassified to profit and loss</b>		
1 Items that will not be reclassified to profit or loss	25.00	50.00
Total Amount of items that will not be reclassified to profit and loss	25.00	50.00
2 Income tax relating to items that will not be reclassified to profit or loss	6.30	12.59
<b>3 Amount of items that will be reclassified to profit and loss</b>		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income	18.70	37.41

## Statement of Asset and Liabilities

Amount in (Lakhs)

	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	<b>Assets</b>	
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	21,530.87
	Capital work-in-progress	583.42
	Investment property	0.00
	Goodwill	0.00
	Other intangible assets	139.34
	Intangible assets under development	307.88
	Biological assets other than bearer plants	0.00
	Investments accounted for using equity method	0.00
	<b>Non-current financial assets</b>	
	Non-current investments	0.33
	Trade receivables, non-current	0.00
	Loans, non-current	0.00
	Other non-current financial assets	1,370.79
	<b>Total non-current financial assets</b>	1,371.12
	Deferred tax assets (net)	1,346.93
	Other non-current assets	3,768.76
	<b>Total non-current assets</b>	29,048.32
<b>2</b>	<b>Current assets</b>	
	Inventories	15,630.76
	<b>Current financial asset</b>	
	Current investments	0.00
	Trade receivables, current	23,193.68
	Cash and cash equivalents	1,197.67
	Bank balance other than cash and cash equivalents	202.84

	Loans, current	0.00
	Other current financial assets	3,419.05
	<b>Total current financial assets</b>	28,013.24
	Current tax assets (net)	0.00
	Other current assets	3,643.52
	<b>Total current assets</b>	47,287.52
3	Non-current assets classified as held for sale	7,550.98
4	Regulatory deferral account debit balances and related deferred tax Assets	0.00
	<b>Total assets</b>	83,886.82
	<b>Equity and liabilities</b>	
1	<b>Equity</b>	
	<b>Equity attributable to owners of parent</b>	
	Equity share capital	1,579.16
	Other equity	47,060.18
	<b>Total equity attributable to owners of parent</b>	48,639.34
	Non controlling interest	
	<b>Total equity</b>	48,639.34
2	<b>Liabilities</b>	
	<b>Non-current liabilities</b>	
	<b>Non-current financial liabilities</b>	
	Borrowings, non-current	5,654.03
	<b>Trade payables, non-current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	0.00
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.00
	<b>Total Trade payable</b>	0.00
	Other non-current financial liabilities	403.60
	<b>Total non-current financial liabilities</b>	6,057.63
	Provisions, non-current	664.80
	Deferred tax liabilities (net)	0.00
	Deferred government grants, Non-current	0.00
	Other non-current liabilities	0.00
	<b>Total non-current liabilities</b>	6,722.43
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	16,468.73

	<b>Trade payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	581.84
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	7,697.42
	<b>Total Trade payable</b>	8,279.26
	Other current financial liabilities	2,036.25
	<b>Total current financial liabilities</b>	26,784.24
	Other current liabilities	140.09
	Provisions, current	52.35
	Current tax liabilities (Net)	0.00
	Deferred government grants, Current	0.00
	<b>Total current liabilities</b>	26,976.68
3	Liabilities directly associated with assets in disposal group classified as held for sale	1,548.37
4	Regulatory deferral account credit balances and related deferred tax liability	0.00
	<b>Total liabilities</b>	35,247.48
	<b>Total equity and liabilities</b>	83,886.82
	Disclosure of notes on assets and liabilities	

## Cash flow statement indirect

Amount in (Lakhs)

Particulars	Half Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	30-09-2025
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
<b>Part I</b>	
<b>Blue color marked fields are non-mandatory.</b>	
<b>1 Statement of cash flows</b>	
<b>Cash flows from used in operating activities</b>	
Profit before tax	3,048.72
<b>2 Adjustments for reconcile profit (loss)</b>	
Adjustments for finance costs	1,078.44
Adjustments for decrease (increase) in inventories	558.01
Adjustments for decrease (increase) in trade receivables, current	1,989.66
Adjustments for decrease (increase) in trade receivables, non-current	0.00
Adjustments for decrease (increase) in other current assets	(227.68)
Adjustments for decrease (increase) in other non-current assets	0.00
Adjustments for other financial assets, non-current	0.00
Adjustments for other financial assets, current	0.00
Adjustments for other bank balances	0.00
Adjustments for increase (decrease) in trade payables, current	0.00
Adjustments for increase (decrease) in trade payables, non-current	0.00
Adjustments for increase (decrease) in other current liabilities	(2,382.49)
Adjustments for increase (decrease) in other non-current liabilities	0.00
Adjustments for depreciation and amortisation expense	1,271.86
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	200.00
Adjustments for provisions, current	0.00
Adjustments for provisions, non-current	0.00
Adjustments for other financial liabilities, current	0.00
Adjustments for other financial liabilities, non-current	0.00
Adjustments for unrealised foreign exchange losses gains	(215.92)

Adjustments for dividend income	0.00
Adjustments for interest income	29.93
Adjustments for share-based payments	0.00
Adjustments for fair value losses (gains)	0.00
Adjustments for undistributed profits of associates	0.00
Other adjustments for which cash effects are investing or financing cash flow	0.00
Other adjustments to reconcile profit (loss)	(224.43)
Other adjustments for non-cash items	7.13
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.00
<b>Total adjustments for reconcile profit (loss)</b>	<b>2,024.65</b>
<b>Net cash flows from (used in) operations</b>	<b>5,073.37</b>
Dividends received	0.00
Interest paid	0.00
Interest received	0.00
Income taxes paid (refund)	54.83
Other inflows (outflows) of cash	0.00
<b>Net cash flows from (used in) operating activities</b>	<b>5,018.54</b>
<b>3 Cash flows from used in investing activities</b>	
Cash flows from losing control of subsidiaries or other businesses	0.00
Cash flows used in obtaining control of subsidiaries or other businesses	810.00
Other cash receipts from sales of equity or debt instruments of other entities	0.00
Other cash payments to acquire equity or debt instruments of other entities	0.00
Other cash receipts from sales of interests in joint ventures	0.00
Other cash payments to acquire interests in joint ventures	0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.00
Proceeds from sales of property, plant and equipment	12.50
Purchase of property, plant and equipment	1,098.42
Proceeds from sales of investment property	0.00
Purchase of investment property	0.00
Proceeds from sales of intangible assets	0.00
Purchase of intangible assets	0.00

	Proceeds from sales of intangible assets under development	0.00
	Purchase of intangible assets under development	0.00
	Proceeds from sales of goodwill	0.00
	Purchase of goodwill	0.00
	Proceeds from biological assets other than bearer plants	0.00
	Purchase of biological assets other than bearer plants	0.00
	Proceeds from government grants	0.00
	Proceeds from sales of other long-term assets	0.00
	Purchase of other long-term assets	0.00
	Cash advances and loans made to other parties	0.00
	Cash receipts from repayment of advances and loans made to other parties	0.00
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.00
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.00
	Dividends received	0.00
	Interest received	29.93
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	(114.02)
	<b>Net cash flows from (used in) investing activities</b>	<b>(1,980.01)</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0.00
	Payments from changes in ownership interests in subsidiaries	0.00
	Proceeds from issuing shares	0.00
	Proceeds from issuing other equity instruments	0.00
	Payments to acquire or redeem entity's shares	0.00
	Payments of other equity instruments	0.00
	Proceeds from exercise of stock options	0.00
	Proceeds from issuing debentures notes bonds etc	0.00
	Proceeds from borrowings	96.15
	Repayments of borrowings	1,041.01
	Payments of lease liabilities	77.94
	Dividends paid	0.00
	Interest paid	1,078.44
	Income taxes paid (refund)	0.00

	Other inflows (outflows) of cash	0.00
	<b>Net cash flows from (used in) financing activities</b>	(2,101.24)
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	937.29
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0.00
	<b>Net increase (decrease) in cash and cash equivalents</b>	937.29
	<b>Cash and cash equivalents cash flow statement at beginning of period</b>	260.38
	<b>Cash and cash equivalents cash flow statement at end of period</b>	1,197.67

## Audit qualification

Sr.	Details of Audit Qualification	Type of Audit Qualification	Frequency of qualification	For Audit Qualification(s) where the impact is quantified by the auditor	For Audit Qualification(s) where the impact is not quantified by the auditor		
				Management's Views	(i) Management's estimation on the impact of audit qualification	(ii) If management is unable to estimate the impact, reasons for the same	Auditors Comments on (i) or (ii) above
No records available							

**Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)**

Amount in (Lakhs)

Sr. No.	Details of the party (listed entity / subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction	
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance
1	Bajaj Healthcare Limited	Mrs. Nihita Bajaj Kumar	Daughter of Mr. Sajankumar Bajaj, Chairman & Managing Director & Sister of Ms. Namrata Bajaj, Whole-Time Director	Any other transaction	Legal & Professional Fees		Approved by the Audit Committee			5.00	5.35	4.27
2	Bajaj Healthcare Limited	Ms. Khushi Jain	Daughter of Mr. Anil Champalal Jain, Managing Director & Sister of Mr. Pakshal Anil Jain, Whole-	Any other transaction	Legal & Professional Fees		Approved by the Audit Committee			2.70	1.80	0.90

			Time Director									
3	Bajaj Healthcare Limited	Mrs. Harshavi Pakshal Jain	Wife of Mr. Pakshal Jain, Whole-Time Director & Daughter-in-law of Mr. Anil Jain, Managing Director	Remuneration			NA			9.55	0.00	0.00
4	Bajaj Healthcare Limited	Taradevi Rameshwari Bajaj Charitable Trust	Charitable Trust	Any other transaction	CSR Expenses		Approved by the Audit Committee			11.00	0.00	0.00
5	Bajaj Healthcare Limited	Genrx Pharmaceuticals Private Limited	Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relatives	Any other transaction	Operating Expenses incurred by Bajaj on behalf of Genrx Pharmaceuticals		Approved by the Audit Committee			61.19	0.00	61.19
6	Bajaj Healthcare Limited	Mr. Sajankumar Bajaj	Chairman & Managing Director	Advance			Approved by the Audit Committee			600.00	0.00	0.00
7	Bajaj Healthcare Limited	Mr. Sajankumar Bajaj	Chairman & Managing Director	Remuneration			NA			212.47	0.00	0.00
8	Bajaj Healthcare Limited	Mr. Anil Champalal Jain	Managing Director	Remuneration			NA			174.97	0.00	0.00
9	Bajaj Healthcare Limited	Ms. Namrata Bajaj	Whole-Time Director	Remuneration			NA			24.06	0.00	0.00
10	Bajaj Healthcare Limited	Mr. Pakshal Jain	Son of Mr. Anil Champalal Jain, Managing Director	Remuneration			NA			24.15	0.00	0.00
<b>Total value of transaction during the reporting period</b>										<b>1,125.09</b>		

## Text Block

<a href="#">Textual Information(1)</a>	<p>The Company has acquired Genrx Pharmaceuticals Private Limited (in Liquidation) as a going concern through Sale Certificate dated 04.04.2025 &amp; Possession Letter dated 05.04.2025. The status of Genrx Pharmaceuticals is in liquidation at ROC, hence there was no Board at the time of acquisition. Genrx Pharmaceuticals requires funding for their operational purposes. On 03.06.2025, the Company filed an application before the National Company Law Tribunal (NCLT), Mumbai, seeking certain reliefs and concessions necessary for the effective takeover of the Genrx Pharmaceuticals Private Limited (in Liquidation), Corporate Debtor and to complete the acquisition as a going concern.</p>
<a href="#">Textual Information(2)</a>	<p>The advance of Rs. 6,00,00,000 given by the Company to Mr. Sajankumar R. Bajaj who is a Promoter, Chairman &amp; MD of the Company which was in the ordinary course of business and in accordance with the provisions of Section 185(3)(a)(i) of the Companies Act, 2013. The said advance was extended as a part of the conditions of service applicable to all employees of the Company, including senior management personnel, under the Company's existing Employee Loan Policy, which provides for such financial assistance in accordance with the service terms. The said advance was repaid before completion of 6 months.</p>

Objects for which funds have been raised and where there has been a deviation, in the following table:

<b>Sr.</b>	<b>Original Object</b>	<b>Modified Object, if any</b>	<b>Original Allocation</b>	<b>Modified allocation, if any</b>	<b>Funds Utilised</b>	<b>Amount of Deviation/ Variation for the quarter according to applicable object</b>	<b>Remarks if any</b>
No records available							